Dimensional Fund Advisors LP Aravive, Inc. Transaction History

Dimensional Fund Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.93 - $1.9 $40,999 - $83,761	-44,085 Reduced 47.86%	48,024 $48,000
Q1 2022 May 13, 2022	SELL	$1.85 - $2.75 $592 - $880	-320 Reduced 0.35%	92,109 $178,000
Q4 2021 Feb 09, 2022	SELL	$2.19 - $4.07 $33,850 - $62,909	-15,457 Reduced 14.33%	92,429 $202,000
Q3 2021 Nov 12, 2021	SELL	$3.67 - $5.8 $325,514 - $514,436	-88,696 Reduced 45.12%	107,886 $401,000
Q2 2021 Aug 12, 2021	SELL	$4.65 - $6.42 $66,397 - $91,671	-14,279 Reduced 6.77%	196,582 $1.18 Million
Q1 2021 May 14, 2021	SELL	$5.11 - $9.24 $12,309 - $22,259	-2,409 Reduced 1.13%	210,861 $1.39 Million
Q4 2020 Feb 25, 2021	BUY	$4.36 - $6.51 $929,857 - $1.39 Million	213,270 New	213,270 $1.2 Million

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.